Related references
Note: Only part of the references are listed.1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
B. G. Levesque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
R. J. Keizer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
N. Vande Casteele et al.
GUT (2012)
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab
U. Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis
A. W. R. van Kuijk et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
E. F. Stange et al.
JOURNAL OF CROHNS & COLITIS (2008)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)